ResMed to Sell MatrixCare for $490M, Named Top Momentum Stock
RMD•ResMed has agreed to sell its MatrixCare care-provider software suite to Frazier Healthcare Partners for $490 million in cash, with the transaction slated to close in the first quarter of fiscal 2027. Analyst style scores identify ResMed as a top momentum stock, highlighting its blend of value, growth and momentum attributes.
1. MatrixCare Divestiture Details
ResMed has agreed to sell its MatrixCare software suite—including MatrixCare, Healthcare First, Citus and home health and hospice solutions—to Frazier Healthcare Partners for $490 million in cash, excluding its Brightree and MEDIFOX DAN software businesses. The transaction is expected to close in the first quarter of ResMed’s 2027 fiscal year.
2. 2030 Strategic Refocus on Sleep Health
The divestiture supports ResMed’s 2030 strategy to target high-growth, scalable opportunities in sleep health, breathing health and connected home-based care. Proceeds will be redirected to R&D, operational scaling and long-term value creation across its AirSense CPAP machines and AirFit masks.
3. Momentum Stock Rating
Analyst style scores rate ResMed as a leading momentum stock by spotlighting its combination of value, growth and momentum attributes. This rating reflects investor confidence in ResMed’s earnings outlook tied to its core sleep health portfolio.
